Restoring immune balance in type 1 diabetes

The Lancet Diabetes and Endocrinology

Volumn 1, Issue 4, 2013, Pages 261-263

  Herold, Kevan C ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALEFACEPT; INTERLEUKIN 1 ANTIBODY; MONOCLONAL ANTIBODY CD3; HYBRID PROTEIN;

B LYMPHOCYTE; CD2+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; EFFECTOR CELL; FLOW CYTOMETRY; HUMAN; IMMUNOLOGICAL TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; LETTER; LYMPHOCYTE FUNCTION; NATURAL KILLER CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; BLOOD; DIABETES MELLITUS, TYPE 1; DRUG DELIVERY SYSTEM; DRUG EFFECTS; FEMALE; IMMUNOLOGICAL MEMORY; MALE; PROCEDURES;

DIABETES MELLITUS, TYPE 1; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; MALE; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 84887625399     PISSN: 22138587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-8587(13)70123-2     Document Type: Letter

References (10)

1. Herold KC, Pescovitz MD, McGee P, et al. Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes. J Immunol 2011, 187:1998-2005.
2. Herold KC, Gitelman SE, Ehlers MR, et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 2013, published online July 8. 10.2337/db13-0345.
3. Rigby M, DiMeglio LA, Rendell MS, et al. Targeting of effector memory T cells with alefacept in new onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol 2013, published online Sept 23. http://dx.doi.org/10.1016/S2213-8587(13)70111-6.
4. Steele C, Hagopian WA, Gitelman S, et al. Insulin secretion in type 1 diabetes. Diabetes 2004, 53:426-433.
5. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003, 139:719-727.
6. Penaranda C, Tang Q, Bluestone JA Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J Immunol 2011, 187:2015-2022.
7. Gitelman SE, Gottlieb PA, Rigby MR, et al. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 2013, for the START Study Team, published online Aug 28. http://dx.doi.org/10.1016/S2213-8587(13)70065-2.
8. Long SA, Rieck M, Sanda S, et al. Rapamycin/IL-2 Combination therapy in patients with type 1 diabetes augments tregs yet transiently impairs beta-cell function. Diabetes 2012, 61:2340-2348.
9. Herold K, Vignali DA, Cooke A, Bluestone J Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol 2013, 13:243-256.
10. Sherry NA, Chen W, Kushner JA, et al. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology 2007, 148:5136-5144.